PREVENTION

Stopping Disease Progression Before It Starts

a woman with headphones drinking water out of a bottle outdoors

First-of-its Kind Partnership Unites World Leaders in Therapeutics and Prevention

This year marked the beginning of a revolutionary new Precision Prevention Partnership between the ADDF and the FINGERS Brain Health Institute (FBHI), which holds the potential to transform the landscape of Alzheimer's prevention and treatment.

The partnership will further accelerate the momentum built by recent breakthroughs in drug and biomarker development by combining the ADDF’s world-class expertise in therapeutics development with the knowledge of the global leader in Alzheimer’s prevention and founder of FBHI, Miia Kivipelto, MD, PhD.

Together, we will bring physicians the tools they need to use patients’ biomarker profiles, combined with their medical and family histories, to tailor drug and lifestyle interventions for maximum effect. These efforts will allow us to lead the way in shaping the future of Alzheimer’s care.

Innovating Prevention Research Around the Globe

Headshot of Miia Kivipelto smiling
Miia Kivipelto, MD, PhD

In addition to her role in the ADDF’s new partnership, Dr. Kivipelto, Founder of the FINGERS Brain Health Institute, a Professor of Clinical Geriatrics at the Karolinska Institute Center for Alzheimer Research, Senior Geriatrician and Director for Research and Development of Medical Unit Aging at Karolinska University Hospital, and member of the ADDF’s Board of Governors, is known for her FINGER trial (Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability) – a perfect example of the innovative prevention research the ADDF seeks out to support.

The landmark study was the first to prove a combination of factors – including exercise, diet, cognitive and social stimulation, and management of vascular and metabolic risk – can prevent cognitive decline by up to 40%. We are excited to be funding the next phase of Dr. Kivipelto’s work, FINGER 2.0, which adds the FDA-approved diabetes drug metformin to the lifestyle interventions originally studied to discern whether this combination provides even greater protection for the aging brain.

Educating Stakeholders Across the Alzheimer’s Universe

In our role as thought leaders in the Alzheimer’s arena, part of our mission is to evaluate and disseminate information on the latest prevention research. The blogs and ratings on our Cognitive Vitality website are designed to deliver science-backed strategies to help people make smarter lifestyle decisions, promote brain health, and potentially ward off disease.

In addition, our Cognitive Vitality Reports spark the thinking of researchers and physicians with their in-depth evaluations performed by our expert team of in-house neuroscientists. These reports cover drugs, drugs-in-development, drug targets, supplements, nutraceuticals, food/drink, non-pharmacologic interventions, and risk factors.